Activity Dates: 10/07/2022 - 10/07/2025
If you are a pharmacist, nurse practitioner or other healthcare professional involved in the comprehensive medication management of psychiatric patients, we invite you to participate in this online course.
With the recent approval by the FDA of esketamine for the treatment of depression (Kim et al., 2019), there is renewed interest in and approval of studies examining other agents with hallucinogenic and psychedelic properties to treat psychiatric and substance use disorders. 3,4-methylenedioxymethamphetamine (MDMA) was examined in a phase III clinical trial for post-traumatic stress disorder (Mitchell et al., 2021) and phase II study examining MDMA-assisted psychotherapy for anxiety (Wolfson et al., 2020). Psilocybin and lysergic acid diethylamide (LSD) are being investigated in several phase II and phase I clinical trials. (Gasser et al.,2014 and Gasser et al., 2015). Psilocybin has recently been designated as a “breakthrough therapy” for treatment-resistant depression and major depressive disorder. (Bock 2020). Ayahuasca, which contains N,N-dimethyltryptamine (DMT) has been studied along with therapy for addiction. (Thomas, et al. 2013) and depression (Palhano-Fontes et al., 2019). Additionally, there are observational studies in México and New Zealand examining the use of ibogaine-assisted therapy in the treatment of opioid use disorder. (Noller et al., 2017 and Brown et al., 2018)
Psychiatric disorders continue to be a major public health crisis with great economic burden by affecting about 350 million people worldwide. A significant number of people have failed many of the traditional medication management treatments or have treatment-resistant disorders. Psychedelic compounds share pharmacological overlap with both SSRIs and atypical antipsychotics through interaction with one or more 5-HT receptors or 5-HT transporters (presynaptic 5-HT1A receptors, postsynaptic 5-HT1A and 5-HT2A receptors).These compounds may provide novel treatment strategies for patients who cannot achieve remission of symptoms or have residual with currents agents or have significant side effects with current treatment options.
To receive ACPE credit for this session, you must:
Upon successful completion, ACPE credit is reported within 24 hours to CPE Monitor although transcripts can be retrieved by participants online in their ACPE Transcript.
AAPP has invested in supporting the most popular web browsers and leveraging software that our members use daily. Beyond PDF downloads, the rest of the system is built on HTML5, a technology that most up-to-date browsers will support. To access AAPP course materials online, you will need:
AAPP web sites no longer fully support Microsoft Internet Explorer or Windows 8.1 and older. We cannot guarantee that the site will function perfectly on every device and configuration, but using the latest version of the software above will greatly improve your experience.
Frederick S. Barrett, PhD
View biographical information and disclosures
The College of Psychiatric and Neurologic Pharmacists is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
AAPP owns the copyright, is licensed or has received permissions for use of, or is otherwise permitted to use copyrighted materials within any CPE activity. Authors and speakers are required to obtain necessary copyright permissions for content in CPE activities. AAPP complies with copyright laws and regulations.
2022 Planning Committee
|
Ericka Crouse, PharmD, BCPP, BCGP, FASHP, FASCP Associate Professor VCU School of Pharmacy Richmond, VA External Consultant Activities, Advisory Panels, Speakers Bureaus, etc.: ASHP - PAM Behavioral Health Committee (volunteer), Editorial Board - The Medical Letter (paid), American Society of Consultant Pharmacists - speak at meetings/webinars on GeroPsych topics (paid), Wolters-Kluwer, paid consultant |
|
Cassandra Davis, PharmD, BCPP, BCPS Mental Health Clinical Pharmacy Specialist Orlando VA Medical Center Orlando, FL No Relevant Financial Relationships to Disclose |
 Megan J. Ehret, PharmD, BCPP, MSBCPP Program Director Professor University of Maryland Baltimore, MD External Consultant Activities, Advisory Panels, Speakers Bureaus, etc.: Psych U Section Advisor, Lexi-Comp Consultant/Reviewer, SMI Adviser; Pharmacist Consultant Educational Grants, Research Grants or Contracts: FDA/University of Maryland CERSI, Maryland Behavioral Health Department, NIH |
 Sarah Melton, PharmD, BCPP, BCACP, FASCPChair Professor of Pharmacy Practice Gatton College of Pharmacy Johnson City, TN Non-Financial Interests: One Care of Southwest Virginia, Virginia Board of Pharmacy, Virginia Opioid Abatement Authority, Overmountain Recovery, Virginia Department of Health Professions Board, Virginia Medicaid Pharmacy and Therapeutics Committee |
Troy Moore, PharmD, MS, BCPP |
|
Erika Titus-Lay, PharmD, BCPP, BCPS Assistant Professor California Northstate University College of Pharmacy Elk Grove, CA Educational Grants, Research Grants or Contracts: Sponsor, ASHP Pharmacy Leadership Scholars Research Grant |
2022 Reviewers
Audrey Abelleira, PharmD, BCPP, BCPS |
David Dadiomov, PharmD, BCPP |
James J. Gasper, PharmD, BCPP |
Cindy A. Gutierrez, PharmD, MS, BCPP |
Dara L. Johnson, PharmD, BCPP, BCACP |
Benjamin Miskle, PharmD |
Marnie Noel, PharmD, BCPP |
All relevant relationships have been mitigated.
All relevant relationships have been mitigated.
Off-Label Use: This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA (see faculty information and disclosures). The opinions expressed in the educational activity do not necessarily represent the views of AAPP and any educational partners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer: Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Presentation-Specific Disclosure: My presentation will include discussion of off-label, experimental, and /or investigational use of drugs or devices: Psilocybin, Lysergic Acid Diethylamide, Dimethyltryptamine
It is the policy of AAPP to ensure independence, balance, objectivity, scientific rigor, and integrity in continuing education activities. Those involved in the development of this continuing education activity have made all reasonable efforts to ensure that information contained herein is accurate in accordance with the latest available scientific knowledge at the time of accreditation of this continuing education activity. Information regarding drugs (e.g., their administration, dosages, contraindications, adverse reactions, interactions, special warnings, and precautions) and drug delivery systems is subject to change, however, and the reader is advised to check the manufacturer’s package insert for information concerning recommended dosage and potential problems or cautions prior to dispensing or administering the drug or using the drug delivery systems.
Fair balance is achieved through ongoing and thorough review of all materials produced by faculty, and all educational and advertising materials produced by supporting organizations, prior to educational offerings. Approval of credit for this continuing education activity does not imply endorsement by AAPP for any product or manufacturer identified.